As of November 7, 2026, 6 holders' latest Schedule 13D or 13G filings report owning 5% or more of CytomX Therapeutics, Inc. The largest reported stake is Fmr LLC's, at 14.6%. 30 filings are on record since July 9, 2025 (Schedule 13G/A, February 5, 2026).
Sell to companies like CytomX Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Bank Of America Corp · Sole voting: 0 · Shared voting: 11,866,012 · Sole dispositive: 0 · Shared dispositive: 11,867,012 · SCHEDULE 13G/A, 2026-10-28
- · Reporting person: Kynam Capital Management, LP · Sole voting: 0 · Shared voting: 21,703,093 · Sole dispositive: 0 · Shared dispositive: 21,703,093 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: Point72 Asset Management, L.P. · Sole voting: 0 · Shared voting: 7,811,033 · Sole dispositive: 0 · Shared dispositive: 7,811,033 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: State Street Corporation · Sole voting: 0 · Shared voting: 11,471,693 · Sole dispositive: 0 · Shared dispositive: 11,747,236 · SCHEDULE 13G, 2026-08-07
- · Holder: Bank Of America Corp · Percent: 7% · SCHEDULE 13G
CytomX Therapeutics, Inc. has 30 Schedule 13D or 13G filings on record since 2025-07-09. 6 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Fmr LLC | 14.6% | 24,688,109 | SCHEDULE 13G/A, 2026-02-05 | 2025-12-31 |
| Kynam Capital Management, LP | 9.96% | 0 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| BlackRock, Inc. | 7.6% | 16,551,452 | SCHEDULE 13G, 2026-07-27 | 2026-06-30 |
| 7% | 15,288,461 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 | |
| Bank Of America Corp | 5.4% | 11,867,012 | SCHEDULE 13G/A, 2026-10-28 | 2026-09-30 |
| State Street Corporation | 5.4% | 11,747,236 | SCHEDULE 13G, 2026-08-07 | 2026-06-30 |
| Perceptive Advisors LLC | 4.6% | 10,098,824 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| Venrock Healthcare Capital Partners III, L.P. | 4.6% | 9,982,124 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| Point72 Asset Management, L.P. | 3.6% | 7,811,033 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| Bvf Partners L P | 3.5% | 5,769,231 | SCHEDULE 13G/A, 2025-07-09 | 2025-07-03 |
| OrbiMed Advisors LLC | 2.1% | 3,525,650 | SCHEDULE 13G/A, 2026-02-17 | 2025-12-31 |
| Seven Fleet Master Fund LP | 0.5% | 1,085,398 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| The Vanguard Group | 0% | 0 | SCHEDULE 13G/A, 2026-03-26 | 2026-03-13 |
| Tang Capital Management, LLC | 0% | 0 | SCHEDULE 13G/A, 2026-02-17 | 2025-12-31 |
Holding shares or following this stake? See who's behind CytomX Therapeutics, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on CytomX Therapeutics, Inc. and the records around it.
CytomX Therapeutics, Inc. elsewhere on the record
- Leadership changes Jul 2026
- Who owns it
Companies that share a holder
- Longitude Capital Partners V, LLC also filed stake reports on 3 other companies: Entera Bio Ltd. (Aug 2026), Mobia Medical, Inc. (May 2026), Veradermics, Incorporated (May 2026)
- Seven Fleet Master Fund LP also filed stake reports on 3 other companies: Entera Bio, Ltd. (the "Issuer") (Aug 2026), Veradermics, Inc (May 2026), CG Oncology, Inc. (Oct 2025)
- Kynam Capital Management, LP also filed stake reports on 8 other companies: Celldex Therapeutics, Inc. (Aug 2026), Vera Therapeutics, Inc. (Aug 2026), Viridian Therapeutics, Inc. (Aug 2026)
Watch CytomX Therapeutics, Inc.
Get an email when CytomX Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on CytomX Therapeutics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on CytomX Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on CytomX Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
31 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Kynam Capital Management, LP | 0 | 21,703,093 | 0 | 21,703,093 | SCHEDULE 13G/A, 2026-08-14 |
| Kynam Capital Management GP, LLC | 0 | 21,703,093 | 0 | 21,703,093 | SCHEDULE 13G/A, 2026-08-14 |
| Yue Tang | 0 | 21,703,093 | 0 | 21,703,093 | SCHEDULE 13G/A, 2026-08-14 |
| BlackRock, Inc. | 16,307,550 | 0 | 16,551,452 | 0 | SCHEDULE 13G, 2026-07-27 |
| Bank Of America Corp | 0 | 11,866,012 | 0 | 11,867,012 | SCHEDULE 13G/A, 2026-10-28 |
| State Street Corporation | 0 | 11,471,693 | 0 | 11,747,236 | SCHEDULE 13G, 2026-08-07 |
| Point72 Asset Management, L.P. | 0 | 7,811,033 | 0 | 7,811,033 | SCHEDULE 13G/A, 2026-08-14 |
| Point72 Capital Advisors, Inc. | 0 | 7,811,033 | 0 | 7,811,033 | SCHEDULE 13G/A, 2026-08-14 |
| Steven A. Cohen | 0 | 7,811,033 | 0 | 7,811,033 | SCHEDULE 13G/A, 2026-08-14 |
The latest filing identifies CytomX Therapeutics, Inc. by CUSIP 23284F105 and gives its principal executive office as 151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA 94080 (SCHEDULE 13G/A, 2026-10-28).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-09 | Bvf Partners L P | 6.8% | SCHEDULE 13G/A |
| 2025-07-09 | Bvf Partners L P | 3.5% | SCHEDULE 13G/A |
| 2025-07-29 | The Vanguard Group | 5.95% | SCHEDULE 13G/A |
| 2025-08-06 | Fmr LLC | 5.9% | SCHEDULE 13G |
| 2025-08-14 | Point72 Asset Management, L.P. | 5.1% | SCHEDULE 13G/A |
| 2025-08-14 | OrbiMed Advisors LLC | 5.4% | SCHEDULE 13G |
| 2025-08-14 | Tang Capital Management, LLC | 7% | SCHEDULE 13G/A |
| 2025-08-21 | Perceptive Advisors LLC | 5.9% | SCHEDULE 13G |
| 2025-11-05 | Fmr LLC | 9.3% | SCHEDULE 13G/A |
| 2025-11-07 | Fmr LLC | 12.4% | SCHEDULE 13G/A |
| 2025-11-14 | Point72 Asset Management, L.P. | 2.5% | SCHEDULE 13G/A |
| 2025-11-14 | Seven Fleet Master Fund LP | 0.02% | SCHEDULE 13G/A |
| 2025-11-14 | Venrock Healthcare Capital Partners III, L.P. | 9.4% | SCHEDULE 13G/A |
| 2026-02-05 | Fmr LLC | 14.6% | SCHEDULE 13G/A |
| 2026-02-17 | OrbiMed Advisors LLC | 2.1% | SCHEDULE 13G/A |
| 2026-02-17 | Tang Capital Management, LLC | 0% | SCHEDULE 13G/A |
| 2026-03-04 | Kynam Capital Management, LP | 5.29% | SCHEDULE 13G |
| 2026-03-26 | The Vanguard Group | 0% | SCHEDULE 13G/A |
| 2026-04-16 | Point72 Asset Management, L.P. | 5% | SCHEDULE 13G |
| 2026-05-15 | Seven Fleet Master Fund LP | 0.5% | SCHEDULE 13G/A |
| 2026-05-15 | Perceptive Advisors LLC | 4.6% | SCHEDULE 13G/A |
| 2026-05-15 | Patrick G. Enright | 7% | SCHEDULE 13G/A |
| 2026-05-15 | Venrock Healthcare Capital Partners III, L.P. | 4.6% | SCHEDULE 13G/A |
| 2026-05-15 | Kynam Capital Management, LP | 6.9% | SCHEDULE 13G/A |
| 2026-07-27 | BlackRock, Inc. | 7.6% | SCHEDULE 13G |
| 2026-08-03 | Bank Of America Corp | 7% | SCHEDULE 13G |
| 2026-08-07 | State Street Corporation | 5.4% | SCHEDULE 13G |
| 2026-08-14 | Point72 Asset Management, L.P. | 3.6% | SCHEDULE 13G/A |
| 2026-08-14 | Kynam Capital Management, LP | 9.96% | SCHEDULE 13G/A |
| 2026-10-28 | Bank Of America Corp | 5.4% | SCHEDULE 13G/A |
Questions about who owns CytomX Therapeutics, Inc.
Who owns CytomX Therapeutics, Inc.?
On this page, 6 holders' latest ownership filings report 5% or more of CytomX Therapeutics, Inc.: Fmr LLC (14.6%, Schedule 13G/A, filed 2026-02-05), Kynam Capital Management, LP (9.96%, Schedule 13G/A, filed 2026-08-14), BlackRock, Inc. (7.6%, Schedule 13G, filed 2026-07-27), Patrick G. Enright (7%, Schedule 13G/A, filed 2026-05-15) and Bank Of America Corp (5.4%, Schedule 13G/A, filed 2026-10-28); 1 more is listed above.
Who are the largest shareholders of CytomX Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of CytomX Therapeutics, Inc. on this page are Fmr LLC (14.6%), Kynam Capital Management, LP (9.96%) and BlackRock, Inc. (7.6%).
When did Fmr LLC buy into CytomX Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Fmr LLC on this page is the Schedule 13G, filed 2025-08-06, reporting 5.9%; its latest, Schedule 13G/A filed 2026-02-05, reports 14.6%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 30 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for CytomX Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| July 27, 2026 | Leadership change: Charles Fuchs appointed, Director | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for CytomX Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.